Wedam SB et al. Antiangiogenic and antitumor effects of bevacizumab in patients with inflammatory and locally advanced breast cancer. JCO 2006;
24(5):769-77. Abstract

Miller KD et al. A randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer: A trial coordinated by the Eastern Cooperative Oncology Group (E2100). SABCS 2005;Abstract 3.

Hope S Rugo, MD

Traina TA et al. Letrozole with bevacizumab is feasible in patients with hormone receptor-positive metastatic breast cancer. ASCO 2006;Abstract 3050.

Rugo HS. Change in circulating endothelial cells predicts progression free survival in patients with hormone receptor positive metastatic breast cancer receiving letrozole and bevacizumab. ASCO 2006;Abstract 3039.

Burstein HJ et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: A randomized phase II study. SABCS 2005;Abstract 4.

I Craig Henderson, MD

Hayes DF et al. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. ASCO 2006;Abstract 510.

Antonio C Wolff, MD

Lyman GH. Guidelines of the National Comprehensive Cancer Network on the use of myeloid growth factors with cancer chemotherapy: A review of the evidence. J Natl Compr Canc Netw 2005;3(4):557-71. Abstract

Vogel CL et al. First and subsequent cycle use of pegfilgrastim prevents febrile neutropenia in patients with breast cancer: A multicenter, double-blind, placebo-controlled phase III study. JCO 2005;23(6):1178-84. Abstract

Smith TJ et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. JCO 2006;24(19):3187-205. Abstract

Giordano SH et al. Congestive heart failure in older women treated with anthracycline chemotherapy. ASCO 2006;Abstract 521.

Shepherd LE et al. Left ventricular function following adjuvant chemotherapy for breast cancer: The NCIC CTG MA5 experience. ASCO 2006;Abstract 522.

Sparano JA et al. Phase III study of doxorubicin- cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node-negative breast cancer: Results of North American Breast Cancer Intergroup Trial E1199. SABCS 2005;Abstract 48.

Thomas G Budd, MD

Bianco AR. Sequential epirubicin-docetaxel-CMF as adjuvant therapy of early breast cancer: Results of the Taxit216 multicenter phase III trial. ASCO 2006;Abstract LBA520.

Crown J. Docetaxel (T) given either concurrently or sequentially to anthracycline-based (A) adjuvant therapy (adjRx) for patients (pts) with node-positive (N+) breast cancer (BrCa). Comparison with non-taxane combination chemotherapy. First results of the BIG 2-98 trial at 5 years median follow-up. ASCO 2006;Abstract LBA519.

Peter M Ravdin, MD, PhD

Swain SM. A step in the right direction. JCO 2006;24(23):3717-8. No abstract available

Paik S et al. Gene expression and benefit of chemotherapy in women with nodenegative, estrogen receptor-positive breast cancer. JCO 2006;24(23):3726-34. Abstract

William J Gradishar, MD

Habel LA et al. A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006;8(3):R25. Abstract

Clifford Hudis, MD

Berry DA et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295(14):1658-67. Abstract

Muss H et al. Toxicity of older and younger patients treated with intensive adjuvant chemotherapy for node-positive breast cancer: The CALGB experience. ASCO 2006;Abstract 559.

Smith I. Trastuzumab following adjuvant chemotherapy in HER2-positive early breast cancer: Disease-free and overall survival after 2 year median follow-up. ASCO 2006;[Special session]. Abstract

Joyce O’Shaughnessy, MD

Jones SE et al. Final analysis: TC has a superior disease-free survival compared to standard AC in 1016 women with early stage breast cancer. SABCS 2005;Abstract 40.

Hayes DF. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. ASCO 2006;Abstract 510.

Charles E Geyer Jr, MD

Geyer CE Jr et al. A Phase III randomized, open-label international study comparing lapatinib and capecitabine vs capecitabine in women with refractory advanced or metastatic breast cancer. ASCO 2006;[Special session]. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. ASCO 2006;Abstract 1.

Knoop A. TOP2A aberrations as predictive and prognostic marker in high-risk breast cancer patients. A randomized DBCG Trial (DBCG89D). ASCO 2006;Abstract 532.

O’Mally FP et al. Prognostic and predictive value of topoisomerase II alpha in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer (NCIC CTG MA.5). ASCO 2006;Abstract 533.

Rowan T Chlebowski, MD, PhD

Ingle J. NCIC CTG MA.17: Intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. ASCO 2006;Abstract 549.

Robert NJ. Updated analysis of NCIC CTG MA.17 (letrozole vs placebo to letrozole vs placebo) post unblinding. ASCO 2006;Abstract 550.

Coombes RC. First mature survival analysis of the Intergroup Exemestane Study: A randomised trial in disease-free, postmenopausal patients with early breast cancer randomized to continue tamoxifen or switch to exemestane following an initial 2-3 years of adjuvant tamoxifen. ASCO 2006;Abstract LBA527.